P0084 Eribulin in patients with advanced urothelial cancer and previously treated with platinum and anti-microtubule chemotherapy: A phase 2 California Cancer Consortium trial von Quinn, D.I, Twardowski, P.W, Ruel, N, Groshen, S.G, Dorff, T.B, Pal, S.K, Stadler, W.M, Gandara, D.R, Lara Jr, P.N, Newman, E.M

Volltext

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model von Nguyen, H G, Yang, J C, Kung, H-J, Shi, X-B, Tilki, D, Lara, P N, DeVere White, R W, Gao, A C, Evans, C P

Volltext

Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients von Lo, E N, Beckett, L A, Pan, C-X, Robles, D, Suga, J M, Sands, J M, Lara, P N

Volltext

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421 von Lara Jr, P.N., Plets, M., Tangen, C., Gertz, E., Vogelzang, N.J., Hussain, M., Twardowski, P.W., Garzotto, M.G., Monk, J.P., Carducci, M., Goldkorn, A., Mack, P.C., Thompson, I., Van Loan, M., Quinn, D.I.

Volltext

Inhibition of Akt pathways in the treatment of prostate cancer von Nelson, E C, Evans, C P, Mack, P C, Devere-White, R W, Lara, Jr, P N

Volltext

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma von Jonasch, E., Hasanov, E., Corn, P.G., Moss, T., Shaw, K.R., Stovall, S., Marcott, V., Gan, B., Bird, S., Wang, X., Do, K.A., Altamirano, P.F., Zurita, A.J., Doyle, L.A., Lara, P.N., Tannir, N.M.

Volltext

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small Cell Lung Cancer von Gandara, D.R, Riess, J.W, Kelly, K, Li, T, Mack, P.C, Lara, P.N

Volltext